Predictive Biomarkers Market By Biomarker Type (Genetic & Genomic Biomarkers, Protein Biomarkers, Pharmacogenomic Biomarkers, Imaging Biomarkers, Other Biomarkers); By Testing Platform (Next-Generation Sequencing, Immunohistochemistry, PCR-Based Testing, In Situ Hybridization/FISH, Companion Diagnostic Assays, Interpretation Software); By Sample Type (Tissue-Based Testing, Blood/Plasma-Based Liquid Biopsy, Other Sample Types); By Application (Oncology, Pharmacogenomics, Cardiovascular Therapy Selection, Autoimmune & Inflammatory Diseases, Neurology, Infectious Diseases); By End User (Diagnostic & Reference Laboratories, Hospitals & Cancer Centers, Pharmaceutical & Biotechnology Companies, CROs & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Predictive Biomarkers Market: Drug-Linked Testing, Genomic Profiling, and Liquid Biopsy Reshape Treatment Selection

The Global Predictive Biomarkers Market was valued at USD 25.7 billion in 2025 and is projected to reach USD 84.45 billion by 2032, growing at a CAGR of 18.53%, according to Strategic Market Research.

 

Predictive biomarkers identify patients more likely to respond to, resist, or develop toxicity from a specific therapy. Prognostic biomarkers estimate disease course independent of treatment selection. HER2 expression in breast cancer, EGFR mutations in non-small-cell lung cancer, RAS mutations in colorectal cancer, and PD-L1 expression across multiple tumors directly guide prescribing decisions.

 

Commercial activity spans immunohistochemistry reagents, PCR assays, fluorescence and in situ hybridization tests, sequencing panels, liquid-biopsy services, pharmacogenomic tests, interpretation software, and companion diagnostic development. A completed clinical report is the most defensible demand unit because one sequencing panel may evaluate hundreds of genes while producing a single treatment-selection result. Counting every reported gene as an individual test would materially overstate utilization.

 

The FDA’s companion diagnostic list, current to February 2026, includes treatment-linked assays for HER2, EGFR, ALK, ROS1, BRAF, KRAS, PD-L1, MSI/dMMR, BRCA, ESR1, FGFR, IDH, NTRK, and RET. Every new assay–drug linkage generates work for test developers, instrument manufacturers, reference laboratories, pathologists, bioinformatics providers, and pharmaceutical diagnostic partners.

 

Cancer Incidence Sets the Upper Limit for Testing Demand

The United States is projected to record 2.11 million new cancer cases and 626,140 cancer deaths in 2026. Major treatment-linked testing populations include 321,910 female breast cancer cases, 229,410 lung and bronchus cancer cases, 333,830 prostate cancer cases, and 158,850 colorectal cancer cases. Global estimates used in the supporting assessment identify approximately 20.64 million new cancer cases and 9.76 million deaths in 2024.

Cancer incidence provides only an upper-level denominator. Tumor stage, histology, treatment line, specimen availability, physician ordering, reimbursement, and access to a matched drug determine whether an incident case becomes a paid predictive-biomarker test.

 

Oncology Accounts for Nearly Three-Quarters of Revenue

Oncology represented an estimated 72.8% of predictive-biomarker revenue in 2025 and is projected to expand at an 11.6% CAGR from 2026 to 2032. Cancer testing commands the largest share because results determine eligibility for targeted drugs, checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors. Advanced cancer patients may require baseline tissue profiling, plasma testing when tissue is inadequate, and additional molecular analysis after progression.

 

Genomic Biomarkers Lead New Assay Development

Genetic and genomic biomarkers held an estimated 46.5% market share in 2025 and are forecast to grow at a 13.2% CAGR through 2032. EGFR, ALK, KRAS, BRAF, BRCA, ESR1, RET, and NTRK results increasingly determine drug selection or exclusion. Protein biomarkers retain a large installed base through HER2, ER/PR, and PD-L1 testing, but new mutation-defined therapies are directing incremental laboratory spending toward sequencing-based services.

 

NGS Replaces Sequential Mutation Testing

Next-generation sequencing generated an estimated 39.4% of 2025 revenue and is projected to grow at a 14.5% CAGR through 2032. NGS conserves limited tissue and replaces several sequential mutation tests with one report. NeoGenomics reported that NGS generated nearly one-third of its clinical revenue in the third quarter of 2025 after NGS revenue increased 24% year over year. PCR and IHC remain important where drug labels require specific assays or payers do not reimburse broad profiling.

 

Tissue Testing Remains Dominant as Plasma Volumes Accelerate

Tissue-based testing accounted for an estimated 61.9% market share in 2025 and is projected to grow at an 8.7% CAGR through 2032. Liquid biopsy is forecast to expand at a 17.0% CAGR as oncologists use plasma when tissue is insufficient and repeat molecular testing after progression. A negative plasma result may still require tissue confirmation because low tumor shedding can conceal an actionable alteration.

 

North America Leads Through FDA-Linked Testing and Reimbursement

North America generated an estimated 42.7% of 2025 market revenue and is expected to grow at a 10.9% CAGR through 2032. FDA companion diagnostic approvals, Medicare NGS coverage, pharmaceutical codevelopment, and established reference laboratories support regional revenue. Asia-Pacific is projected to record the fastest regional CAGR of 14.2%, supported by expanding sequencing capacity, large cancer populations, and a high frequency of selected actionable mutations.

 

Incomplete Lung Cancer Testing Delays Matched Therapy

Non-small-cell lung cancer accounts for approximately 80%–85% of lung cancers, producing an estimated U.S. source population of 183,500–195,000 incident NSCLC cases in 2026. The corresponding global population is approximately 2.11–2.24 million cases based on 2024 lung cancer incidence. Advanced nonsquamous disease can require testing for EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK, HER2, and PD-L1.

A U.S. real-world cohort reported 2020 testing rates of approximately 71% for EGFR, 70% for ALK, 67% for ROS1, 59% for BRAF, and 84% for PD-L1. Only 49% of patients were tested for all five markers assessed. Another analysis of 2,257 patients found that 76.3% had at least one driver-mutation or PD-L1 result before or during first-line treatment. Missed orders and late results increase demand for reflex testing, broader panels, electronic ordering prompts, and shorter laboratory turnaround times.

Regional mutation prevalence influences the number of actionable results generated from the same testing volume. EGFR mutations occur in approximately 49.1% of Asian NSCLC populations versus 12.8% in Europe. Laboratories serving Asian cancer centers can therefore identify more EGFR-positive patients per thousand tests, supporting investment in rapid PCR and NGS workflows.

 

Breast Cancer Testing Extends Beyond Conventional HER2 Positivity

HER2 testing is standard for newly diagnosed invasive breast cancer, while advanced disease increasingly requires PIK3CA, ESR1, BRCA1/2, and other treatment-linked results. HER2-positive disease accounts for about 15%–20% of breast cancers. Applied to projected U.S. incidence, this indicates 48,300–64,400 HER2-positive cases in 2026. Globally, the range is about 365,100–486,800 cases based on 2024 incidence. These biological estimates do not represent completed tests or treated patients.

Actual HER2 testing volume exceeds the positive population because most newly diagnosed invasive tumors are tested regardless of the final result. Laboratories must also distinguish conventional HER2 positivity from HER2-low and other expression categories as drug labels become more specific.

ESR1 testing adds a second testing event for some patients with endocrine-resistant breast cancer. FDA-linked use of Guardant360 CDx for ESR1-mutated advanced disease allows oncologists to identify acquired resistance mutations through plasma after previous endocrine therapy. Testing revenue therefore extends beyond the original diagnostic specimen into later treatment lines.

 

Colorectal Testing Prevents Ineffective Anti-EGFR Use

The United States is projected to record 158,850 colorectal cancer cases in 2026, while the supporting global assessment identifies approximately 2.04 million cases in 2024. Treatment-linked testing concentrates in metastatic disease, where RAS mutations exclude most patients from conventional anti-EGFR treatment and BRAF, MSI/dMMR, HER2, KRAS G12C, and rare fusions can direct other therapies.

A metastatic colorectal cancer analysis reported mutation prevalence of approximately 35.9% for KRAS, 7.1% for BRAF, and 4.1% for NRAS. MSI-H/dMMR occurs in approximately 15% of early-stage colorectal cancers but falls to roughly 5% in metastatic disease. Applying early-stage MSI prevalence to the metastatic treatment population would overstate immunotherapy-related testing demand.

RAS testing also protects payer budgets. Detecting a RAS mutation can prevent use of an expensive anti-EGFR regimen in a patient unlikely to respond, giving exclusion testing direct clinical and financial value.

 

PD-L1 Assay Fragmentation Protects Established Platforms

FDA-linked PD-L1 assays use different antibodies, tissues, scoring methods, and drug-specific thresholds. Results may be reported through Tumor Proportion Score, Combined Positive Score, tumor-cell staining, or immune-cell staining. Depending on the indication, treatment thresholds range from 1% to 50% or use CPS cutoffs of 1 or 10.

Agilent/Dako, Roche/Ventana, and other established pathology suppliers benefit from validated assay–drug relationships, installed instruments, quality-control materials, and pathologist training. Laboratories cannot automatically substitute one PD-L1 assay for another when the replacement lacks evidence for the relevant treatment decision.

 

Liquid Biopsy Generates Additional Tests at Progression

Guardant Health reported approximately 276,000 oncology tests in 2025, an increase of 34% from 2024. Fourth-quarter volume reached approximately 79,000 tests, up 38%, while quarterly oncology revenue increased 30% to USD 189.9 million. First-quarter 2026 oncology revenue subsequently rose 36% to USD 205.0 million. The disclosures include several oncology applications and do not represent total predictive-biomarker demand, but they document the growing use of centralized plasma and tissue profiling.

Clinical sensitivity determines whether plasma replaces tissue or produces another laboratory order. One comparative EGFR study reported 82.35% sensitivity and 100% specificity for a plasma cobas assay, while the comparator plasma approach produced 52.94% sensitivity. Low circulating tumor DNA and low variant abundance can turn a negative plasma result into a tissue follow-up rather than the end of the testing pathway.

 

Pharmacogenomics Builds Defined Non-Oncology Workflows

CYP2C19 genotyping can alter clopidogrel selection by identifying reduced-function metabolizers. HLA-B*57:01 testing is used before abacavir because positive patients face a greater hypersensitivity risk. TPMT and NUDT15 genotypes guide thiopurine dosing by identifying patients at increased risk of severe myelosuppression.

The CPIC 2025–2026 thiopurine guideline updated dosing recommendations for mercaptopurine, thioguanine, and azathioprine and added guidance for patients carrying reduced-function variants in both TPMT and NUDT15. Hospital adoption depends on whether results are available inside prescribing systems and whether payers cover testing before treatment begins.

Cardiovascular imaging measures such as ejection fraction can affect treatment selection, while autoimmune biomarkers are being evaluated for biologic response. These applications lack the density of mandatory assay–drug relationships found in oncology and therefore contribute less revenue.

 

Laboratory-Developed Tests Continue Under a Mixed Regulatory Framework

A federal district court vacated the FDA’s May 2024 laboratory-developed test final rule on March 31, 2025. The FDA restored the relevant regulation to its earlier wording on September 19, 2025. Laboratories continue to operate under CLIA requirements, accreditation standards, payer evidence policies, state rules, and existing medical-device authorities rather than the phased framework proposed in 2024.

The current framework allows laboratories to introduce new panels without following the same pathway as an FDA-approved companion diagnostic, but validation, performance disclosure, and reimbursement remain uneven. Pharmaceutical manufacturers generally select diagnostic partners that can support analytical validation, regulatory submissions, global clinical trials, and commercial-scale testing.

 

Assay–Drug Partnerships Determine Competitive Strength

Roche participates across Ventana tissue pathology, cobas molecular testing, and Foundation Medicine genomic profiling, giving the company exposure to IHC, ISH, PCR, tissue NGS, and liquid-biopsy workflows. Agilent/Dako holds established positions in HER2 and PD-L1 immunohistochemistry, while Thermo Fisher Scientific competes through Oncomine assays and installed sequencing platforms.

Guardant Health competes through plasma and tissue profiling, repeat testing, pharmaceutical partnerships, and multiple FDA companion diagnostic claims. NeoGenomics combines molecular testing, FISH, flow cytometry, and pathology services, while Myriad remains prominent in BRCA and hereditary cancer testing. Qiagen maintains PCR-based therascreen assays, and Abbott, Promega, and Biocartis address cytogenetics, MSI, and rapid molecular workflows.

Instrument placements, reagent sales, centralized test revenue, pharmaceutical services, and completed clinical reports use different commercial units. FDA-linked indications, reimbursed testing volume, turnaround time, installed platforms, clinical data, and drug-development partnerships provide a more reliable basis for competitive assessment.

 

Drug Approvals and Repeat Testing Will Direct Future Revenue

New biomarker-defined therapies will increase baseline profiling and molecular reassessment after progression. NGS will capture a larger share of multi-marker testing, while IHC, ISH, and PCR will remain important where drug labels, reimbursement, turnaround time, or local laboratory infrastructure favor focused assays. Plasma testing will add repeat orders but will not eliminate tissue pathology.

Suppliers that secure assay–drug partnerships, return results before treatment begins, obtain payer coverage, manage limited specimens, and integrate reports into prescribing systems will capture more clinical volume. Forecasts should exclude population screening, purely prognostic signatures, and recurrence-monitoring assays unless the result directly changes treatment. Clear inclusion rules prevent one patient, one panel, and hundreds of reported genes from being counted as separate commercial events.

 

Predictive Biomarkers Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 25.70 Billion
Revenue Forecast in 2032	USD 84.45 Billion
Overall Growth Rate	CAGR of 18.53% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Biomarker Type, By Testing Platform, By Sample Type, By Application, By End User, By Geography
By Biomarker Type	Genetic & Genomic Biomarkers, Protein Biomarkers, Pharmacogenomic Biomarkers, Imaging Biomarkers, Other Biomarkers
By Testing Platform	Next-Generation Sequencing, Immunohistochemistry, PCR-Based Testing, In Situ Hybridization/FISH, Companion Diagnostic Assays, Interpretation Software
By Sample Type	Tissue-Based Testing, Blood/Plasma-Based Liquid Biopsy, Other Sample Types
By Application	Oncology, Pharmacogenomics, Cardiovascular Therapy Selection, Autoimmune & Inflammatory Diseases, Neurology, Infectious Diseases
By End User	Diagnostic & Reference Laboratories, Hospitals & Cancer Centers, Pharmaceutical & Biotechnology Companies, CROs & Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Expansion of drug-linked companion diagnostics Rising adoption of genomic profiling and next-generation sequencing Increasing use of liquid biopsy for repeat testing and treatment-resistance assessment
Customization Option	Available upon request